JP2015507921A - 間葉系幹細胞の培養 - Google Patents
間葉系幹細胞の培養 Download PDFInfo
- Publication number
- JP2015507921A JP2015507921A JP2014556198A JP2014556198A JP2015507921A JP 2015507921 A JP2015507921 A JP 2015507921A JP 2014556198 A JP2014556198 A JP 2014556198A JP 2014556198 A JP2014556198 A JP 2014556198A JP 2015507921 A JP2015507921 A JP 2015507921A
- Authority
- JP
- Japan
- Prior art keywords
- nicotinamide
- cells
- mesenchymal stem
- stem cells
- fgf4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1382—Adipose-derived stem cells [ADSC], adipose stromal stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Developmental Biology & Embryology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
Abstract
Description
(a)本明細書に記載の方法に従って間葉系幹細胞を培養して、培養間葉系幹細胞の集団を生成する工程と、
(b)培養間葉系幹細胞の集団を、分化剤と接触させることによって、対象への移植にとって有用な細胞を生成する工程と
を含む、方法が提供される。
(a)本明細書に記載の方法に従って間葉系幹細胞を増殖させる工程と、
(b)間葉系幹細胞を、分化剤と接触させることによって、移植にとって有用な細胞を生成する工程と
を含む、方法が提供される。
(a)ニコチンアミドを含む培地中で混合細胞集団を培養する工程と、
(b)混合細胞集団から細胞表面分子の発現に基づいて細胞を選択することによって、混合細胞集団からMSCを選択する工程と
を含む、方法が提供される。
VCAM1明るい細胞;
VCAM1中程度の細胞;
VCAM1薄暗い細胞;
STRO−1明るい細胞;
STRO−1中程度の細胞;
STRO−1薄暗い細胞;
CD105明るい細胞;
CD105中程度の細胞;
CD105薄暗い細胞。
それは、レシピエント成体組織系の再構成に必要とされる血液または他の組織の量を軽減する。
方法および実験手順
間葉系幹細胞の単離:骨髄由来および脂肪組織由来間葉細胞を、0.05mg/mlのゲンタマイシン(Sigma)および2mMのL−グルタミン(Biological Industries、Israel)を添加した高グルコースDMEMおよび10%ウシ胎仔血清(FBS、Hyclone、Logan、UT、USA)を含有する増殖培地中でのそのプラスチック接着能力に基づいて単離した。細胞を3〜4日間接着させ、非接着細胞を培地交換を用いて洗浄除去した。さらに、培地を3〜4日毎に新鮮な培地と交換した。
成長因子の存在下で培養した間葉系幹細胞に関するニコチンアミドの分析
材料および方法
間葉系幹細胞を、3回または4回の継代にわたって、ニコチンアミドの存在下および非存在下で特定の成長因子(塩基性線維芽細胞成長因子−bFGF、ヘパリン結合上皮成長因子−HB−EGF、線維芽細胞成長因子4−FGF4および血小板由来成長因子、ホモ二量体、サブユニットB、PDGF−BB)の存在下で選択および培養し、細胞の数およびサイズを算出した。
群1:Ctrl
群2:10ng/mlの成長因子
群3:50ng/mlの成長因子
群4:5mMのNAM
群5:5mMのNAM+10ng/mlの成長因子
群6:5mMのNAM+50ng/mlの成長因子。
図1は、塩基性FGFが間葉系幹細胞の増殖を増加させるニコチンアミドの能力に対する負の効果を有することを示す。
骨髄由来間葉系幹細胞培養物に対するニコチンアミドの効果
本発明者らは、ニコチンアミドが骨髄由来MSCの播種効率(選択)を増加させることを示した。ニコチンアミド中での1回の継代後のこれらの細胞の表現型キャラクタライゼーションを、図11および図13に示す。図15、図17A〜B、図22および図26は、骨髄由来MSCの増殖速度に対するニコチンアミドの効果を示す。低濃度のニコチンアミド(例えば、0.1mM)は、骨髄由来MSCの増殖速度に対する有意でない効果を有していた(図面は示さない)。図20A〜Cおよび図21A〜Bは、ニコチンアミドの存在下で増殖させた間葉系幹細胞が、同一の条件下でニコチンアミドの非存在下で増殖させた間葉系幹細胞よりも小さく、粒度が低いことを示す。
ニコチンアミドは培養された脂肪組織由来間葉細胞の増殖を増加させる
脂肪組織由来MSCの表現型キャラクタライゼーションを、図12に示す。図14および図16に示されるように、ニコチンアミドは培養物中での脂肪由来間葉系幹細胞増殖を実質的に改善した。
ニコチンアミドは培養間葉細胞の組織ホーミングを増加させる
培養間葉細胞のホーミングに対するニコチンアミドの効果を評価するために、NOD/SCIDマウスに、非培養間葉細胞、またはサイトカインと共に培養した3週間後のその全子孫を、ニコチンアミドと共に、またはそれなしに移植する。移植前に、細胞をCFSEで標識する。移植の24時間後、レシピエントマウスのマウス骨髄にホーミングした全CFSE標識細胞およびCFSE標識間葉細胞を、FACSにより定量する。
ニコチンアミドはケモカイン受容体および接着分子の機能を増加させる
細胞のホーミングおよび生着のニコチンアミド媒介性増強における接着分子および関連分子の役割を決定するために、in vitroでの移動および接着分子の機能に対するニコチンアミドの効果を試験することができる。
ニコチンアミドは培養細胞のSCID再増殖能力を増加させる
ニコチンアミド処理を、NOD/SCIDマウスでの再増殖により移植細胞のホーミングおよび生着を増強する能力について試験する。再増殖能を評価するために、NOD/SCIDマウスに、間葉細胞が準最適の移植となり、かつ、サイトカインによる3週間の増殖後に少数のマウスまたはその子孫において間葉細胞が生着しないことを意図した用量範囲にわたって、非培養間葉細胞を移植する(n=12)。ヒト細胞の生着を、移植4週間後に評価する。レシピエント骨髄細胞の0.5%がヒトCD45抗原(CD45+)を発現した場合、マウスを生着陽性として評価する。培養物中のニコチンアミドの存在が所定の用量範囲でマウス中の間葉細胞の優れた、明確な生着をもたらすが、未処理の細胞が生着できないか、またはあまり生着しない場合においては、移植された間葉細胞の生着およびホーミングの増強にニコチンアミドが有効であると結論付けることができる。
間葉系幹細胞に対するニコチンアミドの効果に関するさらなる分析
材料および方法
間葉系幹細胞を、上記のようにプラスチック接着方法を用いて単離し、ウシ胎仔血清、±NAMと共に数回の継代にわたって培養した。細胞を、NAMの存在下で選択した。
図18では、細胞計数に対するニコチンアミドの効果が大きいバッチの間葉系幹細胞に関して明らかであり、大規模商業バッチのMSCを少ない継代で製造することができることを示す。これにより、短い培養時間およびニコチンアミドによる幹細胞特性の保存のおかげで、治療的細胞のより良好な品質が確保される。
培養間葉系幹細胞における成長因子の発現に対する、ニコチンアミドとFGF4との組合せの効果
ニコチンアミドとFGF4との存在下での間葉系幹細胞の培養は、未分化状態に細胞を維持しながら、間葉系幹細胞の増殖能力を相乗的に増加させる(図3A〜D、図4A〜4B、図5A〜5Dおよび図27を参照されたい)。これらの培養物中で増殖させたMSCをさらに特性解析するために、培養培地中へのサイトカインの分泌をELISAにより測定した。
培養物中の脂肪由来間葉系幹細胞に対するニコチンアミドとFGF4との組合せの効果
追加のFGF4を含む、または含まないニコチンアミドと共に培養された脂肪由来間葉系幹細胞における増殖および細胞サイズ分布を、最大4回の継代の培養物中で評価した。
造血幹細胞分化に対するニコチンアミドとFGF4の効果
間葉系幹細胞に対するニコチンアミドとFGF4との組合せの効果が特異的な、または一般化された現象であるか否かを決定するために、造血幹細胞をFGF4およびニコチンアミドと共に、およびそれらなしに培養し、成分の亜集団の分化の程度を細胞表面マーカーにより評価した。
臍帯血由来CD133+造血幹細胞を単離し、初期作用成長因子およびウシ胎仔血清、ニコチンアミドおよび/またはFGF4を添加した培地中で3週間培養した。培養物中で3週間後、細胞を表面マーカー(CD38、CD133、CD19)について染色し、FACS分析により細胞集団を決定した。3週間での全細胞を計数することにより、細胞増殖を評価した。
FGF4は培養物中の造血幹細胞の分化に影響しない:
2.5または5mMのニコチンアミドの存在下で3週間、造血初期前駆細胞(CD133+)を培養した場合、分化した細胞の割合は有意に低下し、幹細胞および前駆細胞画分の増加が明確に観察される(図35、カラム1、2および3を参照されたい)。他方、10〜200ng/mlのFGF4への細胞の曝露は、CD38およびCD133を発現する細胞の画分により示されるように、3週間の培養で分化の程度に対するいかなる効果もない(図35および図36、カラム1および4〜6を参照されたい)。ニコチンアミドを用いるか、または用いないFGF4の添加も、培養物中の全細胞増殖に対するいかなる認識できる効果もなかった(結果は示さない)。
コミットした造血幹細胞が培養中のFGF4への曝露により影響されたかどうかを決定するために、それぞれ、分化し、コミットした骨髄系列およびリンパ系細胞を表す、CD33およびCD19を発現する細胞の存在量を、3週間の培養において測定した。ニコチンアミドはコミットした細胞画分を一貫して減少させたが(図37および図38、レーン1〜3および7〜12を参照されたい)、FGF4のみ、またはニコチンアミドと組み合わせたFGF4の添加は、コミットした骨髄細胞またはリンパ系細胞の存在量に対するいかなる効果もなかった(図37および図38、レーン1、4〜6および7〜12を参照されたい)。
間葉系幹細胞の選択および増殖のための、ニコチンアミド±FGF4の組み合わせた使用、次いで、VCAM1/CD106、CD105またはSTRO−1を用いる選択
材料および方法
単離:骨髄由来および脂肪組織由来間葉細胞を、高グルコースDMEMおよび10%ウシ胎仔血清(FBS、Hyclone、Logan、UT、USA)、0.05mg/mlのゲンタマイシン(Sigma)および2mMのL−グルタミン(Biological Industries、Israel)を含有する増殖培地中でのそのプラスチック接着能力に基づいて単離する。細胞を、ニコチンアミド±FGF4の存在下で3〜4日間接着させ、非接着細胞を培地交換すると共に洗浄除去した。
間葉系幹細胞の選択のためのVCAM1/CD106、CD105またはSTRO−1を用いる選択の前のニコチンアミド±FGF4の組み合わせた使用
材料および方法
骨髄由来および脂肪組織由来MSCの選択:骨髄由来および脂肪組織由来間葉細胞を、直接または間接コンジュゲート化マウス抗ヒト抗体(Miltenyi Biotec)および磁気細胞選別(MACS)を用いたCD105、CD106またはSTRO−1発現により選択する。選択された細胞を、高グルコースDMEMおよび10%ウシ胎仔血清(FBS、Hyclone、Logan、UT、USA)、0.05mg/mlのゲンタマイシン(Sigma)および2mMのL−グルタミン(Biological Industries、Israel)を含有する増殖培地中に6x103個の細胞/cm2の濃度で播種する。細胞を3〜4日間接着させ、非接着細胞を培地交換すると共に洗浄除去した。
Claims (43)
- ニコチンアミドと線維芽細胞成長因子4(FGF4)とを含む培地中で間葉系幹細胞(MSC)の集団を培養することによって、MSCを培養する工程を含む、MSCを培養する方法。
- 前記培地がDMEMを含む、請求項1に記載の方法。
- 前記培地が血清または血小板溶解物を含む、請求項1に記載の方法。
- 前記間葉系幹細胞が、骨髄、脂肪組織、胎盤および臍帯血からなる群から選択される組織に由来する、請求項1に記載の方法。
- 前記ニコチンアミドが、ニコチンアミド、ニコチンアミド類似体、ニコチンアミド代謝物、ニコチンアミド類似体代謝物およびそれらの誘導体からなる群から選択される、請求項1に記載の方法。
- 前記培養がプラスチック表面上で行われる、請求項1に記載の方法。
- 前記MSC集団が不均一な細胞集団中に含まれる、請求項1に記載の方法。
- 前記不均一な細胞集団の少なくとも70%がMSCである、請求項7に記載の方法。
- 前記培地のカルシウム濃度が1.8mMより高い、請求項1に記載の方法。
- 前記培養が少なくとも1週間行われる、請求項1に記載の方法。
- 前記培養が少なくとも3回の継代にわたって行われる、請求項1に記載の方法。
- 前記ニコチンアミドの濃度が1〜20mMである、請求項1に記載の方法。
- 前記培地が血小板由来成長因子(PDGF)を含まない、請求項1に記載の方法。
- 間葉系幹細胞の集団を増殖させる方法であって、細胞増殖にとって十分な期間にわたって間葉系幹細胞の播種された集団を培養する工程を含み、前記期間の少なくとも一部については、ニコチンアミドを含まない培地中で前記培養を行い;前記期間の少なくとも第2の部分については、ニコチンアミドとFGF4とを含む培地中で前記培養を行うことによって、間葉系幹細胞の増殖された集団を生成する、方法。
- 前記増殖が、前記間葉系幹細胞の分化を誘導しない条件下で行われる、請求項14に記載の方法。
- 間葉系幹細胞の前記播種された集団が、ニコチンアミドの非存在下で播種された、請求項14に記載の方法。
- 間葉系幹細胞の前記播種された集団が、ニコチンアミドの存在下で播種された、請求項14に記載の方法。
- 前記培地が、血小板由来成長因子(PDGF)を含まない、請求項14に記載の方法。
- ニコチンアミドを含まない前記培地がFGF4を含まない、請求項14に記載の方法。
- ニコチンアミドを含まない前記培地がFGF4を含む、請求項14に記載の方法。
- ニコチンアミドを含む前記培地中での前記培養が、ニコチンアミドを含まない前記培地中での前記培養の前に行われる、請求項14に記載の方法。
- 前記ニコチンアミドを含まない前記培地中での前記培養が、ニコチンアミドを含む前記培地中での前記培養の前に行われる、請求項14に記載の方法。
- ニコチンアミドを含む前記培地中での前記培養が、少なくとも1日間行われる、請求項14に記載の方法。
- ニコチンアミドを含む前記培地中での前記培養が、少なくとも1週間行われる、請求項14に記載の方法。
- ニコチンアミドを含まない前記培地中での前記培養が、少なくとも1日間行われる、請求項14に記載の方法。
- ニコチンアミドを含まない前記培地中での前記培養が、少なくとも1週間行われる、請求項14に記載の方法。
- ニコチンアミドを含む前記培地中での前記培養が、カルシウムを含む培地中で行われ、前記カルシウムの濃度が1.8mMより高い、請求項14に記載の方法。
- ニコチンアミドを含まない前記培地中での前記培養が、カルシウムを含む培地中で行われ、前記カルシウムの濃度が1.8mMより高い、請求項14に記載の方法。
- 対象への移植にとって有用な細胞を生成する方法であって、
(a)請求項1に記載の方法に従って間葉系幹細胞を培養して、培養間葉系幹細胞の集団を生成する工程と、
(b)培養間葉系幹細胞の前記集団を、分化剤と接触させることによって、対象への移植にとって有用な細胞を生成する工程と
を含む、方法。 - 移植にとって有用な細胞を生成する方法であって、
(a)請求項14に記載の方法に従って間葉系幹細胞を増殖させる工程と
(b)前記間葉系幹細胞を、分化剤と接触させることによって、移植にとって有用な細胞を生成する工程と
を含む、方法。 - 前記分化剤が成長因子を含む、請求項29または30に記載の方法。
- 前記分化剤が、前記分化剤をコードするポリヌクレオチドを含む、請求項29または30に記載の方法。
- 前記ポリヌクレオチドが骨形態形成タンパク質2(BMP2)をコードする、請求項32に記載の方法。
- 請求項1または14に記載の方法に従って生成される間葉系幹細胞の単離された集団。
- 請求項29または30に記載の方法に従って生成される分化した細胞の単離された集団。
- 実質的に均一である、請求項34に記載の間葉系幹細胞の単離された集団。
- 少なくとも40%の細胞がVCAM1/CD106を発現する、請求項34に記載の間葉系幹細胞の単離された集団。
- 少なくとも90%の細胞が20μm未満の直径を有する、請求項34に記載の間葉系幹細胞の単離された集団。
- 同一の条件下であるが、ニコチンアミドの非存在下で生成される間葉系幹細胞よりも粒度が低い、請求項34に記載の間葉系幹細胞の単離された集団。
- 30%未満の細胞がCD45を発現し、95%を超える細胞がCD90を発現し、90%を超える細胞がCD105およびCD44を発現する、請求項34に記載の間葉系幹細胞の単離された集団。
- 疾患または障害を治療する方法であって、治療上有効量の請求項34または35に記載の単離された細胞集団を、それを必要とする対象に移植することによって、前記疾患または障害を治療する工程を含む、方法。
- 前記疾患または障害が、骨または軟骨の疾患、神経変性疾患、心疾患、肝疾患、がん、神経損傷、自己免疫疾患、GvHD、創傷治癒および組織再生からなる群から選択される、請求項41に記載の方法。
- 間葉系幹細胞と、ニコチンアミドおよびFGF4を含む培地とを含む、細胞培養物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261597899P | 2012-02-13 | 2012-02-13 | |
US201261597909P | 2012-02-13 | 2012-02-13 | |
US61/597,909 | 2012-02-13 | ||
US61/597,899 | 2012-02-13 | ||
PCT/IL2013/050136 WO2013121426A1 (en) | 2012-02-13 | 2013-02-13 | Culturing of mesenchymal stem cells |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017230030A Division JP2018064572A (ja) | 2012-02-13 | 2017-11-30 | 間葉系幹細胞の培養 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015507921A true JP2015507921A (ja) | 2015-03-16 |
JP2015507921A5 JP2015507921A5 (ja) | 2016-03-31 |
JP6348848B2 JP6348848B2 (ja) | 2018-06-27 |
Family
ID=47953447
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014556198A Expired - Fee Related JP6348848B2 (ja) | 2012-02-13 | 2013-02-13 | 間葉系幹細胞の増殖 |
JP2017230030A Pending JP2018064572A (ja) | 2012-02-13 | 2017-11-30 | 間葉系幹細胞の培養 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017230030A Pending JP2018064572A (ja) | 2012-02-13 | 2017-11-30 | 間葉系幹細胞の培養 |
Country Status (12)
Country | Link |
---|---|
US (2) | US20150064273A1 (ja) |
EP (2) | EP2814951B1 (ja) |
JP (2) | JP6348848B2 (ja) |
CN (2) | CN104204192A (ja) |
AU (1) | AU2013219945B2 (ja) |
BR (1) | BR112014020119A2 (ja) |
CA (1) | CA2863795A1 (ja) |
HK (2) | HK1199905A1 (ja) |
IL (1) | IL234095B (ja) |
IN (1) | IN2014MN01680A (ja) |
SG (1) | SG11201404608WA (ja) |
WO (2) | WO2013121427A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018110686A1 (ja) * | 2016-12-16 | 2018-06-21 | 有限会社大阪空気機械サービス | 組織治癒剤 |
WO2018143258A1 (ja) | 2017-01-31 | 2018-08-09 | オリエンタル酵母工業株式会社 | 多分化能性幹細胞増殖促進剤 |
JP2018522576A (ja) * | 2015-08-12 | 2018-08-16 | チャ バイオテック カンパニー リミテッド | 向上された臍帯由来付着型幹細胞、その製造方法及びその用途 |
JP2020033333A (ja) * | 2018-08-16 | 2020-03-05 | チャ ユニバーシティ インダストリー−アカデミック コオペレーション ファンデーション | 脳卒中治療用組成物、及びそれをスクリーニングする方法 |
JP2020533011A (ja) * | 2017-09-16 | 2020-11-19 | セルズ フォー セルズ ソシエダッド アノニマ | 特定の臍帯間葉細胞集団を含む組成物を得る方法およびその使用 |
KR20200133367A (ko) | 2018-03-22 | 2020-11-27 | 오리엔탈고우보고오교가부시끼가이샤 | 다분화능성 줄기세포 분화 촉진제 |
JP2020537539A (ja) * | 2017-10-20 | 2020-12-24 | ボーン、セラピューティクス、エスアーBone Thrapeutics Sa | 間葉系幹細胞の分化方法 |
JP2022531356A (ja) * | 2019-05-02 | 2022-07-06 | エスシーエム ライフサイエンス カンパニー リミテッド | hPL含有培地で培養された中間葉幹細胞の培養液を含む化粧料組成物 |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
WO2012162754A1 (en) * | 2011-06-03 | 2012-12-06 | Mesoblast, Inc | Methods of treating or preventing neurological diseases |
JP6607675B2 (ja) * | 2011-07-06 | 2019-11-20 | セル セラピー リミテッド | 中胚葉系列の前駆細胞 |
BR112014020119A2 (pt) | 2012-02-13 | 2020-10-27 | Gamida-Cell Ltd | cultura de células-tronco mesenquimais |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
KR101583569B1 (ko) * | 2013-05-15 | 2016-01-08 | 라정찬 | 정맥 투여용 줄기세포 조성물 |
KR101548956B1 (ko) * | 2013-09-05 | 2015-09-01 | 메디포스트(주) | 세포 크기에 따른 간엽줄기세포 배양방법 |
WO2015066552A1 (en) * | 2013-11-04 | 2015-05-07 | Becton, Dickinson And Company | Immunomodulatory potential of a multipotent stromal cell (msc) population |
CA2944703C (en) * | 2014-04-11 | 2023-09-19 | The Administrators Of The Tulane Educational Fund | Cell-surface marker of early msc aging |
WO2015191545A1 (en) * | 2014-06-09 | 2015-12-17 | University Of Washington | Methods of protection against ischemia reperfusion injury |
US10493105B2 (en) * | 2014-09-11 | 2019-12-03 | Taiwan Mitochondrion Applied Technology Co., Ltd | Isolated adipose-derived mesenchymal stem cells treated with angelica extract or butylidenephthalide, and wherein the cells have an increased mitochondrial membrane potential and a decreased level of IL-8, and methods for treating parkinson's disease |
JP6898706B2 (ja) * | 2015-01-05 | 2021-07-07 | ナショナル ヤン−ミン ユニバーシティ | 肝疾患を治療するための間葉系幹細胞 |
US10894947B1 (en) * | 2016-04-29 | 2021-01-19 | Hope Biosciences, Llc | Method for generating protein rich conditioned medium |
US10959425B2 (en) | 2016-04-29 | 2021-03-30 | Hope Biosciences, Llc | Method of banking stem cells |
US10513689B2 (en) | 2016-04-29 | 2019-12-24 | Hope Biosciences, Llc | Culture media for multipotent stem cells |
US11111480B2 (en) | 2016-04-29 | 2021-09-07 | Hope Biosctences, Llc | Culture media for multipotent stem cells |
WO2018005780A1 (en) | 2016-06-30 | 2018-01-04 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Artificial cells and delivery devices for use in tissue engineering, and related methods |
CN106701671A (zh) * | 2016-11-14 | 2017-05-24 | 天津市康婷生物工程有限公司 | 一种利于间充质干细胞应用于骨再生的培养体系 |
CN106520691A (zh) * | 2016-12-30 | 2017-03-22 | 潍坊医学院 | 一种皮肤间充质干细胞的分离及培养方法 |
EP4364799A3 (en) * | 2017-01-11 | 2024-07-17 | Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung | Mesenchymal stem cell-derived extracellular vesicles and their medical use |
CN110869495B (zh) * | 2017-05-12 | 2023-06-20 | 富士胶片株式会社 | 间充质干细胞的制造方法及其应用 |
CN107083357B (zh) * | 2017-06-16 | 2021-04-02 | 四川农业大学 | 一种诱导培养骨髓间充质干细胞的方法 |
CN108220231A (zh) * | 2018-01-23 | 2018-06-29 | 广州资生生物科技有限公司 | 一种干细胞培养基及其制备方法和应用 |
CN108220161B (zh) * | 2018-01-24 | 2022-06-14 | 北京臻溪谷医学研究中心(有限合伙) | 一种多细胞制备实验室布局方案 |
CN109810943A (zh) * | 2019-03-21 | 2019-05-28 | 河南科技大学 | 一种猪肌源性间充质干细胞分离培养基及分离培养方法 |
US10881693B2 (en) | 2019-04-09 | 2021-01-05 | Combangio, Inc. | Processes for making and using a mesenchymal stem cell derived secretome |
US20200407691A1 (en) * | 2019-06-27 | 2020-12-31 | University Of South Carolina | Methods and Materials for Modulation of Cell Secretome Production and Composition |
CN111518865B (zh) * | 2020-05-29 | 2023-10-03 | 湖州中科朗斯生物技术有限公司 | 一种基于间充质干细胞的皮肤修复活性成分的筛选方法 |
CN112116555B (zh) * | 2020-08-12 | 2024-03-26 | 清华大学深圳国际研究生院 | 间充质干细胞的生理功能的检测方法及其应用 |
CN112516169A (zh) * | 2020-12-17 | 2021-03-19 | 陕西佰傲干细胞再生医学有限公司 | 一种用于治疗肠炎的间充质干细胞及其制备方法 |
CA3135658A1 (en) * | 2020-12-24 | 2022-06-24 | Riam Shammaa | Mesenchymal stem cells for treatment of skin disorders and skin problems |
CN113249315A (zh) * | 2021-05-31 | 2021-08-13 | 上海南滨江细胞生物科技有限公司 | 一种脐血含有间充质干细胞的培养方法 |
US20230256023A1 (en) * | 2022-02-17 | 2023-08-17 | MAM Holdings of West Florida, L.L.C. | DERIVED MULTIPLE ALLOGENEIC PROTEINS PARACRINE SIGNALING (d-MAPPS) REGENERATIVE BIOLOGICS PLATFORM TECHNOLOGY ADJUVANT THERAPY FOR THE PREVENTION AND TARGETED TREATMENT OF CANCER AND OTHER DISORDERS |
CN114703133B (zh) * | 2022-05-10 | 2023-09-19 | 苏州依科赛生物科技股份有限公司 | 一种干细胞专用胎牛血清的筛选工艺 |
CN115305234B (zh) * | 2022-09-28 | 2023-01-17 | 呈诺再生医学科技(北京)有限公司 | 一种制备间充质干细胞的方法、间充质干细胞和应用 |
WO2024120329A1 (zh) * | 2022-12-06 | 2024-06-13 | 苏州血霁生物科技有限公司 | 一种分化血小板的方法、培养基及应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090065814A (ko) * | 2007-12-18 | 2009-06-23 | 동국대학교 산학협력단 | 탯줄 유래의 중간엽 줄기세포를 이용한 간-특이기능이 있는간세포의 제조방법 및 이로부터 제조된 탯줄 유래 간세포 |
Family Cites Families (249)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US3715345A (en) | 1970-08-03 | 1973-02-06 | Lilly Co Eli | Glucagon separation process |
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3876623A (en) | 1973-05-09 | 1975-04-08 | Lilly Co Eli | Process for purifying insulin |
US3863008A (en) | 1973-06-11 | 1975-01-28 | American Home Prod | Somatostatin as stimulant of luteinizing hormone secretion |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
US4476301A (en) | 1982-04-29 | 1984-10-09 | Centre National De La Recherche Scientifique | Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon |
US4687808A (en) | 1982-08-12 | 1987-08-18 | Biospecific Technologies, Inc. | Activation of biocompatible polymers with biologicals whose binding complements are pathological effectors |
IL68218A (en) | 1983-03-23 | 1985-12-31 | Univ Ramot | Compositions for cartilage repair comprising embryonal chondrocytes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US5550111A (en) | 1984-07-11 | 1996-08-27 | Temple University-Of The Commonwealth System Of Higher Education | Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US5405938A (en) | 1989-12-20 | 1995-04-11 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
IL79289A (en) | 1985-07-05 | 1992-01-15 | Whitehead Biomedical Inst | Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus |
GB8606913D0 (en) | 1986-03-20 | 1986-04-23 | Hider R C | Treatment of sickle cell disease |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP0260032B1 (en) | 1986-09-08 | 1994-01-26 | Ajinomoto Co., Inc. | Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers |
US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5166320A (en) | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
US4806484A (en) | 1987-08-07 | 1989-02-21 | Igb Products, Ltd. | Perfusion airlift bioreactor |
WO1989002468A1 (en) | 1987-09-11 | 1989-03-23 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
US4924624A (en) | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
US5188897A (en) | 1987-10-22 | 1993-02-23 | Temple University Of The Commonwealth System Of Higher Education | Encapsulated 2',5'-phosphorothioate oligoadenylates |
EP0348458B1 (en) | 1987-11-30 | 1997-04-09 | University Of Iowa Research Foundation | Dna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes |
US5403711A (en) | 1987-11-30 | 1995-04-04 | University Of Iowa Research Foundation | Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved |
ATE110108T1 (de) | 1987-12-11 | 1994-09-15 | Whitehead Biomedical Inst | Genetische modifizierung von endothelialen zellen. |
JP2917998B2 (ja) | 1988-02-05 | 1999-07-12 | ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ | 修飾された肝細胞およびその用途 |
JPH01222780A (ja) | 1988-03-02 | 1989-09-06 | Tosoh Corp | ウロキナーゼ前駆体様蛋白質のリフォールディング方法 |
JPH03503894A (ja) | 1988-03-25 | 1991-08-29 | ユニバーシィティ オブ バージニア アランミ パテンツ ファウンデイション | オリゴヌクレオチド n‐アルキルホスホラミデート |
US5081035A (en) | 1988-04-18 | 1992-01-14 | The University Of Michigan | Bioreactor system |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
US5399493A (en) | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
US5437994A (en) | 1989-06-15 | 1995-08-01 | Regents Of The University Of Michigan | Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
US5264562A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
US5623065A (en) | 1990-08-13 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5220007A (en) | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
US5612211A (en) | 1990-06-08 | 1997-03-18 | New York University | Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors |
US6326198B1 (en) | 1990-06-14 | 2001-12-04 | Regents Of The University Of Michigan | Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells |
US5623070A (en) | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
US5618704A (en) | 1990-07-27 | 1997-04-08 | Isis Pharmacueticals, Inc. | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling |
US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
US5677437A (en) | 1990-07-27 | 1997-10-14 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5541307A (en) | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
HU217036B (hu) | 1990-08-03 | 1999-11-29 | Sanofi | Eljárás génexpresszió gátlására alkalmas vegyületek előállítására |
US5177196A (en) | 1990-08-16 | 1993-01-05 | Microprobe Corporation | Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof |
DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5214134A (en) | 1990-09-12 | 1993-05-25 | Sterling Winthrop Inc. | Process of linking nucleosides with a siloxane bridge |
US5561225A (en) | 1990-09-19 | 1996-10-01 | Southern Research Institute | Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages |
CA2092002A1 (en) | 1990-09-20 | 1992-03-21 | Mark Matteucci | Modified internucleoside linkages |
AU659824B2 (en) | 1990-10-31 | 1995-06-01 | Cell Genesys, Inc. | Retroviral vectors useful for gene therapy |
US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5851832A (en) | 1991-07-08 | 1998-12-22 | Neurospheres, Ltd. | In vitro growth and proliferation of multipotent neural stem cells and their progeny |
US5571799A (en) | 1991-08-12 | 1996-11-05 | Basco, Ltd. | (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response |
WO1993009220A1 (en) | 1991-11-06 | 1993-05-13 | Correa Paulo N | Cell culture medium |
US5700922A (en) | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
ATE225847T1 (de) | 1992-03-04 | 2002-10-15 | Univ Michigan | Verfahren,zusammensetzungen und vorrichtungen zur erhaltung und zur züchtung menschlicher stammzellen und/oder hämatopoetischer zellen |
US5792751A (en) | 1992-04-13 | 1998-08-11 | Baylor College Of Medicine | Tranformation of cells associated with fluid spaces |
US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
US5434257A (en) | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
US5320963A (en) | 1992-11-25 | 1994-06-14 | National Research Council Of Canada | Bioreactor for the perfusion culture of cells |
US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
WO1994018991A1 (en) | 1993-02-19 | 1994-09-01 | Celtrix Pharmaceuticals, Inc. | EXPANSION OF STEM CELLS IN LONG TERM BONE MARROW CULTURES BY NEUTRALIZATION OF TGF-$g(b) |
US5654186A (en) | 1993-02-26 | 1997-08-05 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
GB9304618D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
WO1994022891A1 (en) | 1993-03-31 | 1994-10-13 | Sterling Winthrop Inc. | Oligonucleotides with amide linkages replacing phosphodiester linkages |
US5342781A (en) | 1993-07-15 | 1994-08-30 | Su Wei Wen W | External-loop perfusion air-lift bioreactor |
US5378725A (en) | 1993-07-19 | 1995-01-03 | The Arizona Board Of Regents | Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof |
AU7515294A (en) | 1993-07-28 | 1995-02-28 | Fred Hutchinson Cancer Research Center | Creating novel hematopoietic cell lines by expressing altered retinoic acid receptors |
US5504103A (en) | 1993-08-25 | 1996-04-02 | Eli Lilly And Company | Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
US5789543A (en) | 1993-12-30 | 1998-08-04 | President And Fellows Of Harvard College | Vertebrate embryonic pattern-inducing proteins and uses related thereto |
US5599705A (en) | 1993-11-16 | 1997-02-04 | Cameron; Robert B. | In vitro method for producing differentiated universally compatible mature human blood cells |
ATE196311T1 (de) | 1993-12-09 | 2000-09-15 | Univ Jefferson | Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen |
US6165747A (en) | 1993-12-30 | 2000-12-26 | President & Fellows Of Harvard College | Nucleic acids encoding hedgehog proteins |
US6261786B1 (en) | 1993-12-30 | 2001-07-17 | Imperial Cancer Res. Technology | Screening assays for hedgehog agonists and antagonists |
US6271363B1 (en) | 1993-12-30 | 2001-08-07 | President & Fellows Of Harvard College | Nucleic acids encoding hedgehog proteins |
EP0743981A4 (en) | 1994-02-09 | 1999-09-08 | Unisyn Technologies Inc | HIGH-RESOLUTION CELL CULTURE BIOREACTOR AND ITS USE |
US5631219A (en) | 1994-03-08 | 1997-05-20 | Somatogen, Inc. | Method of stimulating hematopoiesis with hemoglobin |
CA2162465A1 (en) | 1994-03-11 | 1995-09-14 | Craig Sandstrom | Flow-through bioreactor with grooves for cell retention |
US5625050A (en) | 1994-03-31 | 1997-04-29 | Amgen Inc. | Modified oligonucleotides and intermediates useful in nucleic acid therapeutics |
US5489304A (en) | 1994-04-19 | 1996-02-06 | Brigham & Women's Hospital | Method of skin regeneration using a collagen-glycosaminoglycan matrix and cultured epithelial autograft |
US5480906A (en) | 1994-07-01 | 1996-01-02 | Eli Lilly And Company | Stereochemical Wortmannin derivatives |
US5807718A (en) | 1994-12-02 | 1998-09-15 | The Scripps Research Institute | Enzymatic DNA molecules |
US5770378A (en) | 1994-12-30 | 1998-06-23 | Ligand Pharmaceuticals, Inc. | Tricyclic retinoids, methods for their production and use |
US5736396A (en) | 1995-01-24 | 1998-04-07 | Case Western Reserve University | Lineage-directed induction of human mesenchymal stem cell differentiation |
US5741899A (en) | 1995-02-02 | 1998-04-21 | Cell Genesys, Inc. | Chimeric receptors comprising janus kinase for regulating cellular pro liferation |
US5716616A (en) | 1995-03-28 | 1998-02-10 | Thomas Jefferson University | Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects |
US5733541A (en) | 1995-04-21 | 1998-03-31 | The Regent Of The University Of Michigan | Hematopoietic cells: compositions and methods |
US5925567A (en) | 1995-05-19 | 1999-07-20 | T. Breeders, Inc. | Selective expansion of target cell populations |
US5674750A (en) | 1995-05-19 | 1997-10-07 | T. Breeders | Continuous selective clonogenic expansion of relatively undifferentiated cells |
US5728581A (en) | 1995-06-07 | 1998-03-17 | Systemix, Inc. | Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein |
US6680166B1 (en) | 1995-06-07 | 2004-01-20 | Claudy Jean Paul Mullon | Dual fiber bioreactor |
US5712154A (en) | 1995-06-07 | 1998-01-27 | W.R. Grace & Co.-Conn. | Dual fiber bioreactor |
US6306575B1 (en) | 1995-06-16 | 2001-10-23 | Stemcell Technologies, Inc. | Methods for preparing enriched human hematopoietic cell preparations |
JP3638958B2 (ja) | 1995-07-28 | 2005-04-13 | アプルス株式会社 | ランセットの刺通深さを調節するためのアッセンブリ |
US5652356A (en) | 1995-08-17 | 1997-07-29 | Hybridon, Inc. | Inverted chimeric and hybrid oligonucleotides |
US6117850A (en) | 1995-08-28 | 2000-09-12 | The Collaborative Group, Ltd. | Mobilization of peripheral blood precursor cells by β(1,3)-glucan |
US6218128B1 (en) | 1997-09-12 | 2001-04-17 | Allergan Sales, Inc. | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities |
US5776699A (en) | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
US6008204A (en) | 1995-09-01 | 1999-12-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US5958954A (en) | 1995-09-01 | 1999-09-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US5952345A (en) | 1995-09-01 | 1999-09-14 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US6329169B1 (en) | 1995-09-29 | 2001-12-11 | Human Genome Sciences, Inc. | Nucleic acid molecules encoding cytostatin II |
FR2739777B1 (fr) | 1995-10-11 | 1997-11-14 | Cird Galderma | Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose |
EP0938332A4 (en) | 1996-03-01 | 2003-05-28 | Imclone Systems Inc | USE OF DELTA-LIKE PROTEINS TO INHIBIT THE DIFFERENTIATION OF STEM CELLS |
US5877207A (en) | 1996-03-11 | 1999-03-02 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
CA2248142A1 (en) | 1996-03-12 | 1997-09-18 | Life Technologies, Inc. | Hematopoietic cell culture nutrient supplement |
US6043092A (en) | 1996-03-18 | 2000-03-28 | University Of Pittsburgh | Cell culture media for mammalian cells |
US5945309A (en) | 1996-03-19 | 1999-08-31 | Human Genome Sciences, Inc. | Cytostatin III nucleic acids encoding |
TW442459B (en) | 1996-04-15 | 2001-06-23 | Hoffmann La Roche | Retinoid compounds, pharmaceutical composition comprising same and process for the preparation thereof |
US6455678B1 (en) | 1996-04-26 | 2002-09-24 | Amcell Corporation | Human hematopoietic stem and progenitor cell antigen |
CA2252524A1 (en) | 1996-04-29 | 1997-11-06 | Leuven Research & Development Vzw | Pluripotent rabbit embryonic stem (es) cell lines and their use in the generation of chimeric rabbits |
US5851984A (en) | 1996-08-16 | 1998-12-22 | Genentech, Inc. | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
CA2263817A1 (en) | 1996-08-28 | 1998-03-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Therapeutic combinations of rar antagonists and rxr agonists and use thereof |
US5945337A (en) | 1996-10-18 | 1999-08-31 | Quality Biological, Inc. | Method for culturing CD34+ cells in a serum-free medium |
CA2274469C (en) | 1996-12-10 | 2009-09-01 | Tony Peled | Serum-derived factor inducing cell differentiation and medical uses thereof |
US6335195B1 (en) | 1997-01-28 | 2002-01-01 | Maret Corporation | Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
US6294330B1 (en) | 1997-01-31 | 2001-09-25 | Odyssey Pharmaceuticals Inc. | Protein fragment complementation assays for the detection of biological or drug interactions |
CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
US20030215445A1 (en) | 1997-05-23 | 2003-11-20 | Ginette Serrero | Methods and compositions for inhibiting the growth of hematopoietic malignant cells |
US6372473B1 (en) | 1997-05-28 | 2002-04-16 | Human Genome Sciences, Inc. | Tissue plasminogen activator-like protease |
JP2002513295A (ja) | 1997-07-08 | 2002-05-08 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | 123種類のヒト分泌タンパク質 |
IT1293827B1 (it) | 1997-08-07 | 1999-03-10 | Dompe Spa | Metodo per l'espansione ex vivo di cellule staminali emopoietiche |
US6440734B1 (en) | 1998-09-25 | 2002-08-27 | Cytomatrix, Llc | Methods and devices for the long-term culture of hematopoietic progenitor cells |
FR2769491B1 (fr) | 1997-10-15 | 2000-01-07 | Patrick Sangouard | Sphincter artificiel reglable a commande magnetique |
ZA9810122B (en) | 1997-11-12 | 1999-05-12 | Hoffmann La Roche | Treatment of T-helper cell type 2 mediated immune diseases |
US6248587B1 (en) | 1997-11-26 | 2001-06-19 | University Of Southern Cailfornia | Method for promoting mesenchymal stem and lineage-specific cell proliferation |
US6962698B1 (en) | 1998-02-17 | 2005-11-08 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
IL137757A0 (en) | 1998-02-17 | 2001-10-31 | Gamida Cell Ltd | Method of controlling proliferation and differentiation of stem and progenitor cells |
US6886568B2 (en) | 1998-04-08 | 2005-05-03 | The Johns Hopkins University | Method for fabricating cell-containing implants |
US6413773B1 (en) | 1998-06-01 | 2002-07-02 | The Regents Of The University Of California | Phosphatidylinositol 3-kinase inhibitors as stimulators of endocrine differentiation |
AU4336599A (en) | 1998-06-08 | 1999-12-30 | Osiris Therapeutics, Inc. | (in vitro) maintenance of hematopoietic stem cells |
AU4336499A (en) | 1998-06-08 | 1999-12-30 | Osiris Therapeutics, Inc. | Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells |
US20020002269A1 (en) | 1998-09-29 | 2002-01-03 | Jeffrey D. Milbrandt | Artemin, a neurotrophic factor |
JP2003523166A (ja) | 1998-09-29 | 2003-08-05 | ガミダ セル リミテッド | 幹細胞および前駆細胞の増殖と分化を制御する方法 |
US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
CA2254429A1 (en) | 1998-11-19 | 2000-05-19 | Tully Michael Underhill | Compositions for promoting chondrogenesis |
CA2361201A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
EP2311938B1 (en) | 1999-02-04 | 2016-04-06 | Pluristem Ltd. | Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells |
JP4926320B2 (ja) | 1999-04-28 | 2012-05-09 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Vegfの選択的阻害による癌処置のための組成物および方法 |
DE19919242A1 (de) | 1999-04-28 | 2000-11-02 | Creavis Tech & Innovation Gmbh | Modulare Zellträgersysteme für dreidimensionales Zellwachstum |
WO2000073421A2 (en) | 1999-06-02 | 2000-12-07 | Lifebank Services, L.L.C. | Methods of isolation, cryopreservation, and therapeutic use of human amniotic epithelial cells |
US6652872B2 (en) | 1999-07-06 | 2003-11-25 | Ramat At Tel Aviv University Ltd. | Scaffold formed of tissue treated to eliminate cellular and cytosolic elements |
US20020159984A1 (en) | 1999-11-12 | 2002-10-31 | Quality Biological, Inc. | Cultivation of cells for long term engraftment |
US6541249B2 (en) | 1999-12-22 | 2003-04-01 | Human Genome Sciences, Inc. | Immortalized human stromal cell lines |
US6303374B1 (en) | 2000-01-18 | 2001-10-16 | Isis Pharmaceuticals Inc. | Antisense modulation of caspase 3 expression |
WO2001094549A2 (en) | 2000-06-05 | 2001-12-13 | The Burnham Institute | Methods of differentiating and protecting cells by modulating the p38/mef2 pathway |
JP2004504834A (ja) | 2000-08-01 | 2004-02-19 | イスム リサーチ ディベロップメント カンパニー | 胚性細胞の定方向分化 |
US7198940B2 (en) | 2000-10-25 | 2007-04-03 | Shot Hardware Optimization Technology, Inc. | Bioreactor apparatus and cell culturing system |
ES2171131B1 (es) | 2000-11-10 | 2003-12-16 | Idebio S L | Plaguicida biologico a base de quitosano |
US6642019B1 (en) | 2000-11-22 | 2003-11-04 | Synthecan, Inc. | Vessel, preferably spherical or oblate spherical for growing or culturing cells, cellular aggregates, tissues and organoids and methods for using same |
EP2336300B1 (en) | 2001-02-14 | 2015-07-08 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
EP1385935A4 (en) | 2001-03-29 | 2004-09-15 | Ixion Biotechnology Inc | METHOD FOR TRANSDIFFERENTIATION OF NON-PANCREATIC STEM CELLS IN THE PANCREAS DIFFERENTIATION PATHWAY |
JP2004533449A (ja) | 2001-05-11 | 2004-11-04 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム | Cd26を発現している細胞に関連する疾患の治療としての抗cd26モノクローナル抗体 |
US20030017134A1 (en) | 2001-06-19 | 2003-01-23 | Technion Research And Development Foundation Ltd. | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
DE10131388B4 (de) | 2001-06-28 | 2004-07-08 | Infineon Technologies Ag | Integrierter dynamischer Speicher und Verfahren zum Betrieb desselben |
CA2351156A1 (en) | 2001-07-04 | 2003-01-04 | Peter W. Zandstra | A bioprocess for the generation of pluripotent cell derived cells and tissues |
EP1424389A4 (en) | 2001-08-07 | 2004-08-25 | Kirin Brewery | PROCESS FOR THE PREPARATION OF MULTIPOTENT HEMATOPOIETIC STEM CELLS |
WO2003035618A2 (en) | 2001-10-24 | 2003-05-01 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
US6887401B2 (en) | 2001-11-05 | 2005-05-03 | Essilor International Compagnie General D'optique | Method for making transparent polythiourethane substrates in particular optical substrates |
AUPR892501A0 (en) | 2001-11-16 | 2001-12-13 | Peter Maccallum Cancer Institute, The | Method of enhancing self renewal of stem cells and uses thereof |
US7514075B2 (en) | 2001-12-07 | 2009-04-07 | Cytori Therapeutics, Inc. | Systems and methods for separating and concentrating adipose derived stem cells from tissue |
US20050095228A1 (en) | 2001-12-07 | 2005-05-05 | Fraser John K. | Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders |
DE10162814B4 (de) | 2001-12-19 | 2005-06-23 | Henkel Kgaa | Rekonstruiertes Haarfollikelmodell |
IL152904A0 (en) | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
WO2003062404A1 (en) | 2002-01-25 | 2003-07-31 | Gamida-Cell Ltd. | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby |
TWI314928B (en) | 2002-02-28 | 2009-09-21 | Novartis A | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors |
EP1485464A4 (en) | 2002-03-18 | 2006-11-29 | Gamida Cell Ltd | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
US7247477B2 (en) | 2002-04-16 | 2007-07-24 | Technion Research & Development Foundation Ltd. | Methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells |
JP2006508692A (ja) | 2002-08-19 | 2006-03-16 | ガミダ セル リミテッド | 単核細胞培養物における造血幹細胞集団のエクスビボ拡大 |
US20050054097A1 (en) | 2002-11-17 | 2005-03-10 | Tony Peled | EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures |
US7470538B2 (en) | 2002-12-05 | 2008-12-30 | Case Western Reserve University | Cell-based therapies for ischemia |
EP1601759A4 (en) | 2003-03-07 | 2007-02-14 | Gamida Cell Ltd | EXPANSION OF RENEWABLE STEM CELL POPULATIONS USING PI-3 KINASE MODULATORS |
US20040247574A1 (en) | 2003-05-27 | 2004-12-09 | Christopherson Kent W. | Methods for enhancing stem cell engraftment during transplantation |
WO2005007799A2 (en) | 2003-07-17 | 2005-01-27 | Gamida-Cell Ltd. | Methods for ex-vivo expanding stem/progenitor cells |
IL161903A0 (en) | 2003-07-17 | 2005-11-20 | Gamida Cell Ltd | Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs |
US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
WO2005085422A1 (en) | 2004-02-27 | 2005-09-15 | Michigan State University | Adult stem cells and uses thereof |
JP2007528226A (ja) | 2004-03-10 | 2007-10-11 | リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニア | 胚幹細胞の増殖用組成物および方法 |
WO2006030442A2 (en) * | 2004-09-16 | 2006-03-23 | Gamida-Cell Ltd. | Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells |
WO2006050270A2 (en) | 2004-11-02 | 2006-05-11 | The Government Of The United States Of America As Represented By The Secretary Department Of Health & Human Services | Compositions and methods for treating hyperproliferative disorders |
RU2007132733A (ru) | 2005-01-31 | 2009-03-10 | Когнейт Терапьютикс, Инк. (Us) | Стромальные клетки, выделенные из жировой ткани взрослого организма, проявляющие свойства эндотелиальных клеток |
WO2007063545A2 (en) | 2005-11-29 | 2007-06-07 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
US20100021434A1 (en) | 2005-12-08 | 2010-01-28 | Ramot At Tel Aviv University Ltd. | Isolated Oligodendrocyte-Like Cells and Populations Comprising Same for the Treatment of CNS Diseases |
EP2617428A1 (en) * | 2006-08-15 | 2013-07-24 | Agency for Science, Technology and Research | Mesenchymal stem cell conditioned medium |
WO2008056368A2 (en) | 2006-11-09 | 2008-05-15 | Gamida-Cell Ltd. | Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases |
US20090257987A1 (en) | 2008-04-10 | 2009-10-15 | Ramot At Tel Aviv University Ltd. | Method of generating dopamine-secreting cells |
US8062632B2 (en) | 2008-06-23 | 2011-11-22 | National Yang-Ming University | Systems and methods for making hepatocytes from extrahepatic somatic stem cells and use thereof |
TWI397585B (zh) | 2008-07-16 | 2013-06-01 | Univ Nat Taiwan | 細胞培養方法及其應用 |
GB0818725D0 (en) | 2008-10-13 | 2008-11-19 | Habib Nagy A | Pharmaceutical composition |
PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
JP5606008B2 (ja) | 2009-04-13 | 2014-10-15 | 三菱重工業株式会社 | 骨髄間質細胞及び間葉系幹細胞の培養方法、中枢神経系疾患治療用の移植細胞の製造方法 |
EP2333047A1 (en) | 2009-12-09 | 2011-06-15 | Fresenius Medical Care Deutschland GmbH | Adult stem cell derived conditioned medium and/or adult stem cells for use in the therapeutic treatment of a tumor disease |
BR112012016203A2 (pt) | 2009-12-29 | 2019-09-24 | Gamida Cell Ltd | "métodos para melhoria da proliferaçõ e atividade das células exterminadoras naturais" |
EP2566566B1 (en) | 2010-05-03 | 2017-09-06 | The Texas A&M University System | Adult stem cells/progenitor cells and stem cell proteins for treatment of eye injuries and diseases |
BR112014020119A2 (pt) | 2012-02-13 | 2020-10-27 | Gamida-Cell Ltd | cultura de células-tronco mesenquimais |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
-
2013
- 2013-02-13 BR BR112014020119-6A patent/BR112014020119A2/pt not_active Application Discontinuation
- 2013-02-13 JP JP2014556198A patent/JP6348848B2/ja not_active Expired - Fee Related
- 2013-02-13 SG SG11201404608WA patent/SG11201404608WA/en unknown
- 2013-02-13 CN CN201380014921.7A patent/CN104204192A/zh active Pending
- 2013-02-13 CN CN201380016363.8A patent/CN104204193B/zh not_active Expired - Fee Related
- 2013-02-13 WO PCT/IL2013/050137 patent/WO2013121427A1/en active Application Filing
- 2013-02-13 EP EP13712603.3A patent/EP2814951B1/en active Active
- 2013-02-13 WO PCT/IL2013/050136 patent/WO2013121426A1/en active Application Filing
- 2013-02-13 AU AU2013219945A patent/AU2013219945B2/en not_active Ceased
- 2013-02-13 CA CA 2863795 patent/CA2863795A1/en not_active Abandoned
- 2013-02-13 EP EP13711559.8A patent/EP2814950A1/en not_active Withdrawn
- 2013-02-13 US US14/378,221 patent/US20150064273A1/en not_active Abandoned
- 2013-02-13 US US14/378,235 patent/US10047345B2/en not_active Expired - Fee Related
- 2013-02-13 IN IN1680MUN2014 patent/IN2014MN01680A/en unknown
-
2014
- 2014-08-13 IL IL234095A patent/IL234095B/en active IP Right Grant
-
2015
- 2015-01-13 HK HK15100365.0A patent/HK1199905A1/xx not_active IP Right Cessation
- 2015-03-26 HK HK15103074.6A patent/HK1202581A1/xx unknown
-
2017
- 2017-11-30 JP JP2017230030A patent/JP2018064572A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090065814A (ko) * | 2007-12-18 | 2009-06-23 | 동국대학교 산학협력단 | 탯줄 유래의 중간엽 줄기세포를 이용한 간-특이기능이 있는간세포의 제조방법 및 이로부터 제조된 탯줄 유래 간세포 |
Non-Patent Citations (4)
Title |
---|
BONORA-CENTELLES A., CELL TRANSPLANTATION, vol. V18 N12, JPN5015003905, 1 January 2009 (2009-01-01), US, pages 319 - 1340 * |
CELL TRANSPLANT., vol. 18, no. 12, JPN5015003905, 2009, pages 1319 - 1340 * |
LANGENBECKS ARCH. SURG., vol. 394, no. 5, JPN5015003904, 2009, pages 915 - 970 * |
LANGENBECK'S ARCHIVES OF SURGERY, vol. V394 N5, JPN5015003904, 30 July 2009 (2009-07-30), DE, pages 15 - 970 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018522576A (ja) * | 2015-08-12 | 2018-08-16 | チャ バイオテック カンパニー リミテッド | 向上された臍帯由来付着型幹細胞、その製造方法及びその用途 |
US11690877B2 (en) | 2015-08-12 | 2023-07-04 | Cha Biotech Co., Ltd. | Umbilical cord-derived adherent stem cells, preparation method therefor, and use thereof |
JP2020072725A (ja) * | 2015-08-12 | 2020-05-14 | チャ バイオテック カンパニー リミテッド | 向上された臍帯由来付着型幹細胞、その製造方法及びその用途 |
JPWO2018110686A1 (ja) * | 2016-12-16 | 2019-10-24 | 有限会社大阪空気機械サービス | 組織治癒剤 |
WO2018110686A1 (ja) * | 2016-12-16 | 2018-06-21 | 有限会社大阪空気機械サービス | 組織治癒剤 |
WO2018143258A1 (ja) | 2017-01-31 | 2018-08-09 | オリエンタル酵母工業株式会社 | 多分化能性幹細胞増殖促進剤 |
KR20190112760A (ko) | 2017-01-31 | 2019-10-07 | 오리엔탈고우보고오교가부시끼가이샤 | 다분화능성 줄기세포 증식 촉진제 |
US11634690B2 (en) | 2017-01-31 | 2023-04-25 | Oriental Yeast Co., Ltd. | Agent for accelerating growth of pluripotent stem cells |
JP7218947B2 (ja) | 2017-09-16 | 2023-02-07 | セルズ フォー セルズ ソシエダッド アノニマ | 特定の臍帯間葉細胞集団を含む組成物を得る方法およびその使用 |
JP2020533011A (ja) * | 2017-09-16 | 2020-11-19 | セルズ フォー セルズ ソシエダッド アノニマ | 特定の臍帯間葉細胞集団を含む組成物を得る方法およびその使用 |
JP2020537539A (ja) * | 2017-10-20 | 2020-12-24 | ボーン、セラピューティクス、エスアーBone Thrapeutics Sa | 間葉系幹細胞の分化方法 |
JP7039711B2 (ja) | 2017-10-20 | 2022-03-22 | ボーン、セラピューティクス、エスアー | 間葉系幹細胞の分化方法 |
KR20200133367A (ko) | 2018-03-22 | 2020-11-27 | 오리엔탈고우보고오교가부시끼가이샤 | 다분화능성 줄기세포 분화 촉진제 |
US11814652B2 (en) | 2018-03-22 | 2023-11-14 | Oriental Yeast Co., Ltd. | Pluripotent stem cell differentiation-promoting agent |
JP2021181469A (ja) * | 2018-08-16 | 2021-11-25 | チャ ユニバーシティ インダストリー−アカデミック コオペレーション ファンデーション | 脳卒中治療用組成物、及びそれをスクリーニングする方法 |
JP2020033333A (ja) * | 2018-08-16 | 2020-03-05 | チャ ユニバーシティ インダストリー−アカデミック コオペレーション ファンデーション | 脳卒中治療用組成物、及びそれをスクリーニングする方法 |
JP2022531356A (ja) * | 2019-05-02 | 2022-07-06 | エスシーエム ライフサイエンス カンパニー リミテッド | hPL含有培地で培養された中間葉幹細胞の培養液を含む化粧料組成物 |
JP7291427B2 (ja) | 2019-05-02 | 2023-06-15 | エスシーエム ライフサイエンス カンパニー リミテッド | hPL含有培地で培養された中間葉幹細胞の培養液を含む化粧料組成物 |
Also Published As
Publication number | Publication date |
---|---|
CA2863795A1 (en) | 2013-08-22 |
SG11201404608WA (en) | 2014-09-26 |
EP2814951B1 (en) | 2019-04-03 |
US20150064273A1 (en) | 2015-03-05 |
WO2013121427A1 (en) | 2013-08-22 |
CN104204193B (zh) | 2016-10-26 |
IL234095A0 (en) | 2014-09-30 |
CN104204192A (zh) | 2014-12-10 |
IL234095B (en) | 2018-06-28 |
JP6348848B2 (ja) | 2018-06-27 |
WO2013121426A1 (en) | 2013-08-22 |
US20150004146A1 (en) | 2015-01-01 |
EP2814950A1 (en) | 2014-12-24 |
JP2018064572A (ja) | 2018-04-26 |
US10047345B2 (en) | 2018-08-14 |
BR112014020119A2 (pt) | 2020-10-27 |
EP2814951A1 (en) | 2014-12-24 |
IN2014MN01680A (ja) | 2015-07-03 |
AU2013219945A1 (en) | 2014-08-28 |
HK1202581A1 (en) | 2015-10-02 |
HK1199905A1 (en) | 2015-07-24 |
AU2013219945B2 (en) | 2017-12-07 |
CN104204193A (zh) | 2014-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6348848B2 (ja) | 間葉系幹細胞の増殖 | |
Xiao et al. | Clonal characterization of bone marrow derived stem cells and their application for bone regeneration | |
Braun et al. | Evaluation of the osteogenic and chondrogenic differentiation capacities of equine adipose tissue-derived mesenchymal stem cells | |
Trivedi et al. | Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells | |
JP4180228B2 (ja) | 脂肪組織由来の間質細胞に関する多様な中胚葉系統分化能およびその使用 | |
Chong et al. | Human peripheral blood derived mesenchymal stem cells demonstrate similar characteristics and chondrogenic differentiation potential to bone marrow derived mesenchymal stem cells | |
JP5732011B2 (ja) | 非骨軟骨性の間葉組織由来の多能性細胞の同定および単離 | |
Zhu et al. | The comparition of biological characteristics and multilineage differentiation of bone marrow and adipose derived Mesenchymal stem cells | |
Gottipamula et al. | Isolation, expansion and characterization of bone marrow-derived mesenchymal stromal cells in serum-free conditions | |
US7374937B1 (en) | Isolation and expansion of human marrow stromal cells | |
JP6882161B2 (ja) | 改善された幹細胞組成物 | |
US20190071637A1 (en) | Colony forming medium and use thereof | |
JP3762975B2 (ja) | 単球由来多能性細胞momc | |
Baksh et al. | A non‐contact suspension culture approach to the culture of osteogenic cells derived from a CD49elow subpopulation of human bone marrow‐derived cells | |
US20220127577A1 (en) | Xeno-free generation of tissue-specific progenitor cells | |
US20120064040A1 (en) | Serum free culture medium and supplement | |
KR20110095218A (ko) | PI3K/AKT/GSK3 경로를 통해 성체줄기세포의 증식, 다분화능 및 재프로그래밍을 촉진하는 CD49f | |
WO2021227573A1 (zh) | 无异源培养基及使用其扩增间充质干细胞的方法 | |
Lanza et al. | Immunosuppressive properties of mesenchymal stromal cells | |
Niknam et al. | A Simple High Yield Technique for Isolation of Wharton’s Jelly-derived Mesenchymal Stem Cell | |
Juntunen | Development of Adipose-Derived Stromal/stem Cell–Based Therapies: Effects of donor weight and culture conditions on cell characteristics and testing the efficacy in stroke models | |
AU2013362880A1 (en) | Methods of generating cells with multilineage potential | |
Ferro | Isolation, characterization and Ex-Vivo expansion of human synovial tissue derived-mesenchymal stem/stromal cells | |
Patrikoski | Insights into the use of adipose stem cells for clinical cell therapy: Novel culturing conditions and characterization of multipotency and immunogenic properties | |
Pittenger | Mesenchymal Stem Cells from Bone Marrow |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150619 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160209 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160209 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170316 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170801 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171130 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20171207 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180208 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180508 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180601 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6348848 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |